Company news

AC Immune SA news in 2026

AC Immune SA's news releases, calls and decks from 2026, newest first.

View company

AC Immune Third Quarter 2026 Financial and Corporate Update

November 4, 2026

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

August 11, 2026

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026

July 7, 2026

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease

June 30, 2026

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

June 11, 2026

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

May 22, 2026

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

May 12, 2026

AC Immune First Quarter 2026 Financial and Corporate Updates

April 30, 2026

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

April 30, 2026

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

April 6, 2026

AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026

March 18, 2026

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

March 12, 2026

AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026

March 4, 2026

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor

February 23, 2026

Decks in 2026